Liuchun Wang

State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Effect of hypercalcemia on immune system in patients with non-small cell lung cancer.

Effect of hypercalcemia on immune system in patients with non-small cell lung cancer.

Journal: Cytokine

Published: December 28, 2025

Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway.

Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway.

Journal: Cancer biology & medicine

Published: October 24, 2025

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 22, 2024

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.

Journal: BMC medicine

Published: September 26, 2024

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

Journal: Molecular cancer

Published: April 18, 2023

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.

Journal: EBioMedicine

Published: January 24, 2022

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.

Journal: Cancer letters

Published: September 18, 2020

Prognostic Significance of Combined Biomarkers in Small Cell Lung Cancer.

Prognostic Significance of Combined Biomarkers in Small Cell Lung Cancer.

Journal: Clinical laboratory

Published: September 09, 2020

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements.

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: January 24, 2019

CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study.

CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study.

Journal: Cancer medicine

Published: March 15, 2018

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.

Journal: Journal of Cancer

Published: May 21, 2017

Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.

Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.

Journal: Thoracic cancer

Published: February 11, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026